Morgan Stanley Adjusts Price Target on Moderna to $95 From $89

Moderna Inc. (MRNA) shares rose 4.78% on October 7, 2026, driven by positive mRNA pipeline data and upcoming inclusion in the Nasdaq-100 index. The company reported quarterly revenue of $1.92B, but with significant losses. Traders are watching MRNA for its potential as a growth platform with catalysts like the index inclusion and cancer vaccine developments.

Moderna Inc. (MRNA) stock rose 4.82% after being added to the Nasdaq-100 index. The company reported a net loss of $782M but has strong cash reserves. Positive data for its cancer vaccine and a new COO appointment also influenced trading. MRNA's stock has been volatile, with a recent uptrend and a 6-7% drop on the management change news.

Tempus Inc. (TEM) expanded its collaboration with Moderna (MRNA) and Merck (MRK) to support the development of a cancer vaccine. Tempus will manage sample collection and provide NGS services. The company also partnered with Bristol Myers Squibb (BMY) to improve clinical trial design. Additionally, Tempus acquired Personalis (PSNL) for $1.5 billion to enhance cancer monitoring. TEM shares were down 1.94% to $70.58 at the time of publication.

Tempus, Moderna, and Merck (MSD) expanded their collaboration to support the potential commercialization of intismeran autogene, an investigational mRNA-based therapy for melanoma and other cancers. Tempus will manage sample collection and sequencing. Phase 3 trial results showed the therapy met primary and key secondary endpoints, improving recurrence-free and distant metastasis-free survival. Financial terms were not disclosed.

Novavax (NVAX) and Moderna (MRNA) shares fell 11% and 6% respectively on Wednesday after sharp gains the prior day due to a suspected plague case in Russia. The WHO assesses the public health risk as low, and Citi notes vaccine companies are sensitive to headlines. BioNTech (BNTX) showed limited movement. Citi prefers companies focused on other therapeutic areas.

Moderna's shares rose 6.95% to $203.21 ahead of its inclusion in the Nasdaq 100. The Nasdaq 100 tracks 100 large non-financial companies, with over $800 billion in assets under management. Citi downgraded Moderna to 'sell' with a $80 target price, citing high market expectations for its cancer pipeline. Moderna's market cap is about $75 billion, and its tokenized shares also increased.